Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cervical pessary vs cervical cerclage Birthweight · women with singleton pregnancies at risk of cervical insufficiency Cervical pessary for preventing preterm birth in singleton pregnancies (2022) · Cochrane | no estimate extracted | NR | No studies |
Cervical pessary vs no treatment Harm to offspring from the intervention · women with singleton pregnancies at risk of cervical insufficiency Cervical pessary for preventing preterm birth in singleton pregnancies (2022) · Cochrane | no estimate extracted | NR | No studies |
Cervical pessary vs no treatment Birthweight · women with singleton pregnancies at risk of cervical insufficiency Cervical pessary for preventing preterm birth in singleton pregnancies (2022) · Cochrane | no estimate extracted | NR | No studies |
Lateral postures vs other postures Neonatal encephalopathy (as defined by trialists · fetal malposition in labour Maternal postures for fetal malposition in labour for improving the health of mothers and their infants (2022) · Cochrane | no estimate extracted | NR | No studies |
Lateral postures vs other postures Need for respiratory support · fetal malposition in labour Maternal postures for fetal malposition in labour for improving the health of mothers and their infants (2022) · Cochrane | no estimate extracted | NR | No studies |
Lateral postures vs other postures Neonatal jaundice requiring phototherapy · fetal malposition in labour Maternal postures for fetal malposition in labour for improving the health of mothers and their infants (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical antibiotics vs another topical antibiotic or placebo Change in pain intensity from baseline to 1 month · children and adults with corneal abrasion Antibiotic prophylaxis for corneal abrasion (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical antibiotics vs another topical antibiotic or placebo Recurrent corneal erosion within 1 year · children and adults with corneal abrasion Antibiotic prophylaxis for corneal abrasion (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical antibiotics vs another topical antibiotic or placebo Change in visual acuity from baseline to 1 year, or loss of 1 or more lines of best‐corrected visual acuity at 1 month · children and adults with corneal abrasion Antibiotic prophylaxis for corneal abrasion (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical antibiotics vs another topical antibiotic or placebo Quality of life at 1 month · children and adults with corneal abrasion Antibiotic prophylaxis for corneal abrasion (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention or placebo Secondary malignant neoplasms · adults with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention Progression‐free survival · children with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention Quality of life · children with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention or placebo Quality of life · adults with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Aerobic exercise vs no exercise or placebo exercise Cardiovascularevents · adults undergoing maintenance dialysis Exercise training for adults undergoing maintenance dialysis (2022) · Cochrane | no estimate extracted | NR | No studies |
Resistance exercise vs no exercise or placebo exercise Death (any cause) · adults undergoing maintenance dialysis Exercise training for adults undergoing maintenance dialysis (2022) · Cochrane | no estimate extracted | NR | No studies |
Resistance exercise vs no exercise or placebo exercise Cardiovascular events · adults undergoing maintenance dialysis Exercise training for adults undergoing maintenance dialysis (2022) · Cochrane | no estimate extracted | NR | No studies |
Any exercise vs no exercise or placebo exercise Cardiovascularevents · adults undergoing maintenance dialysis Exercise training for adults undergoing maintenance dialysis (2022) · Cochrane | no estimate extracted | NR | No studies |
Combined aerobic and resistance exercise vs no exercise or placebo exercise Death (any cause) · adults undergoing maintenance dialysis Exercise training for adults undergoing maintenance dialysis (2022) · Cochrane | no estimate extracted | NR | No studies |
Combined aerobic and resistance exercise vs no exercise or placebo exercise Cardiovascular events · adults undergoing maintenance dialysis Exercise training for adults undergoing maintenance dialysis (2022) · Cochrane | no estimate extracted | NR | No studies |
Combined aerobic and resistance exercise vs no exercise or placebo exercise Fatigue · adults undergoing maintenance dialysis Exercise training for adults undergoing maintenance dialysis (2022) · Cochrane | no estimate extracted | NR | No studies |
Synbiotics vs placebo GI function · adult solid organ transplant recipients (kidney) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs placebo Death · adult solid organ transplant recipients (liver) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Synbiotics vs prebiotics GI function · adult solid organ transplant recipients (liver) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Synbiotics vs prebiotics Graft health · adult solid organ transplant recipients (liver) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Synbiotics vs placebo Graft health · adult solid organ transplant recipients (kidney) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Synbiotics vs placebo Adverse events · adult solid organ transplant recipients (kidney) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Synbiotics vs placebo Serious adverse events · adult solid organ transplant recipients (kidney) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Synbiotics vs placebo Death · adult solid organ transplant recipients (kidney) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs placebo GI function · adult solid organ transplant recipients (liver) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs placebo Graft health · adult solid organ transplant recipients (liver) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs placebo Adverse events · adult solid organ transplant recipients (liver) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs placebo Serious adverse events · adult solid organ transplant recipients (liver) Synbiotics, prebiotics and probiotics for solid organ transplant recipients (2022) · Cochrane | no estimate extracted | NR | No studies |
Steroids with or without azathioprine vs cyclosporine A Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Steroids with or without azathioprine vs cyclosporine A Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroid Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) Â · NIIPPU Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroid Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroid Proportion of participants achieving steroid‐sparing control (higher number of events is better) · NIIPPU Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs mycophenolate Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Test result · people with presumptive pulmonary tuberculosisRole: an initial testIndex test: Xpert MTB/XDRThreshold for index test:… Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones,… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Test result · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin… Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones,… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Test result · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis positive by Xpert… Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones,… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Test result · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis‐positive by Xpert… Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones,… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Test result · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin… Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones,… (2022) · Cochrane | no estimate extracted | NR | No studies |
NBI + WLC TURBT vs WLC TURBT Time to disease progression · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive… (2022) · Cochrane | no estimate extracted | NR | No studies |
NBI + WLC TURBT vs WLC TURBT Time to death from bladder cancer · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive… (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Admission to hospital within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Outcomes · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |